


## GSK319347A

<b>Cat. No.:</b>	HY-14682		
<b>CAS No.:</b>	862812-98-4		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>19</sub> N <sub>3</sub> O <sub>5</sub> S <sub>2</sub>		
<b>Molecular Weight:</b>	469.53		
<b>Target:</b>	IKK		
<b>Pathway:</b>	NF-κB		
<b>Storage:</b>	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 45 mg/mL (95.84 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		2.1298 mL	10.6489 mL	21.2979 mL
		<b>5 mM</b>		0.4260 mL	2.1298 mL	4.2596 mL
	<b>10 mM</b>		0.2130 mL	1.0649 mL	2.1298 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.25 mg/mL (4.79 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.25 mg/mL (4.79 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	GSK319347A is a dual inhibitor of TBK1 and IKKε with IC <sub>50</sub> s of 93 nM and 469 nM, respectively. GSK319347A also inhibits IKK2 with an IC <sub>50</sub> of 790 nM.		
<b>IC<sub>50</sub> &amp; Target</b>	TBK1 93 nM (IC <sub>50</sub> )	IKK-ε 469 nM (IC <sub>50</sub> )	IKK2 790 nM (IC <sub>50</sub> )
<b>In Vitro</b>	GSK319347A (Compound 1) inhibits TBK1 enzyme with an IC <sub>50</sub> of 93 nM, which also translates into good cell potency (72 nM). Moreover, IKK-3 Inhibitor exhibits excellent selectivity against cell-cycle kinases CDK2 and AurB <sup>[1]</sup> . IKK-3 Inhibitor (Compound 13) is a novel IκB kinase 2 (IKK2) inhibitor with an IC <sub>50</sub> of 790 nM <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

---

## CUSTOMER VALIDATION

- Theranostics. 2020 Jan 16;10(5):2358-2373.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Johannes JW, et al. Discovery of 6-aryl-azabenzimidazoles that inhibit the TBK1/IKK- $\epsilon$  kinases. *Bioorg Med Chem Lett*. 2014 Feb 15;24(4):1138-43.

[2]. Xie HZ, et al. Pharmacophore modeling and hybrid virtual screening for the discovery of novel I $\kappa$ B kinase 2 (IKK2) inhibitors. *J Biomol Struct Dyn*. 2011 Aug;29(1):165-79.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA